1. Home
  2. CRNX vs MEOH Comparison

CRNX vs MEOH Comparison

Compare CRNX & MEOH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

HOLD

Current Price

$38.78

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Logo Methanex Corporation

MEOH

Methanex Corporation

HOLD

Current Price

$65.28

Market Cap

3.8B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRNX
MEOH
Founded
2008
1968
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Chemicals
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
3.8B
IPO Year
2018
1995

Fundamental Metrics

Financial Performance
Metric
CRNX
MEOH
Price
$38.78
$65.28
Analyst Decision
Strong Buy
Buy
Analyst Count
8
9
Target Price
$76.75
$58.33
AVG Volume (30 Days)
971.8K
1.6M
Earning Date
05-07-2026
04-29-2026
Dividend Yield
N/A
1.17%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,039,000.00
N/A
Revenue This Year
$720.10
$25.43
Revenue Next Year
$184.67
N/A
P/E Ratio
N/A
$16.44
Revenue Growth
N/A
N/A
52 Week Low
$25.83
$31.57
52 Week High
$57.99
$66.75

Technical Indicators

Market Signals
Indicator
CRNX
MEOH
Relative Strength Index (RSI) 50.04 63.41
Support Level $33.19 $46.36
Resistance Level $45.32 $66.75
Average True Range (ATR) 1.49 2.22
MACD -0.02 0.47
Stochastic Oscillator 35.09 98.16

Price Performance

Historical Comparison
CRNX
MEOH

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

About MEOH Methanex Corporation

Methanex Corp manufactures and sells methanol. Its customers use methanol as a feedstock to produce end-products including adhesives, foams, solvents, and windshield washer fluids. The firm also sells its products to the oil refining industry, where the methanol is blended with gasoline to produce a high-octane fuel or blended as a component of biodiesel. It distributes its products through an extensive supply chain that includes the operation of port terminals, tankers, barges, rail cars, trucks, and pipelines. The company generates the majority of its revenue from Europe.

Share on Social Networks: